Amrutanjan Health Care Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 20%)
- Efficient capital deployment (ROCE 31.4%)
- Virtually debt-free
- Near 52-week low — potential value zone (₹476)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
AMRUTANJAN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.59% | 50.59% | 50.58% | 46.52% | 46.52% | 46.52% |
| FII | 0.80% | 1.38% | 1.55% | 2.34% | 2.30% | 2.30% |
| DII | 7.24% | 7.29% | 7.32% | 10.60% | 11.13% | 11.41% |
| Public | 41.19% | 40.66% | 40.47% | 40.50% | 40.01% | 39.75% |
| Others | 0.18% | 0.07% | 0.07% | 0.04% | 0.04% | 0.04% |
Latest News
All newsAmrutanjan Health Care receives credit rating update
*Amrutanjan Health Care receives credit rating update.* The company's latest credit assessment has been disclosed in a regulatory filing. While no **financial figures** or rating specifics are mentioned, this reflects routine credit monitoring. Investors may review the detailed report for risk evaluation. 📊 *STOCKS:* $AMRUTANJAN | 🏢 *SECTOR:* Corporate | #LOWIMPACT #CreditRating
Amrutanjan receives ESG ratings update
*Amrutanjan receives ESG ratings update* as per a recent NSE corporate filing. The ESG assessment highlights the company’s environmental, social, and governance performance metrics. While no **financial figures** or strategic changes were disclosed, the rating may influence ESG-focused investor interest. 📊 *STOCKS:* $AMRUTANJAN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Amrutanjan files BRSR for FY 2025-26
*Amrutanjan files BRSR for FY 2025-26* as part of its sustainability disclosure. The BRSR (Business Responsibility and Sustainability Report) is a mandatory filing for top 1,000 listed companies by market cap. This update reflects compliance activity with no immediate financial implications. No operational or financial changes are indicated. 📊 *STOCKS:* $AMRUTANJAN | 🏢 *SECTOR:* Corporate | #LOWIMPACT #ESG
Amrutanjan Health Care to hold shareholder meeting
*Amrutanjan Health Care to hold shareholder meeting on September 23, 2026.* The event is scheduled for discussing key corporate matters. No financial impact is expected from the meeting. Routine corporate disclosure as per regulatory norms. 📊 *STOCKS:* $AMRUTANJAN | 🏢 *SECTOR:* FMCG | #LOWIMPACT #ShareholderMeeting
About Amrutanjan Health Care Limited
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
HealthcarePharmaceuticals & Biotechnology